Do analysts prefer INCR or MBRX?

Moleculin Biotech has a consensus price target of $3.00, indicating a potential upside of 468.29%. Given Moleculin Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Moleculin Biotech is more favorable than InterCure. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InterCure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Moleculin Biotech 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Is INCR or MBRX more profitable?

InterCure's return on equity of 0.00% beat Moleculin Biotech's return on equity. Company Net Margins Return on Equity Return on Assets InterCure N/A N/A N/A Moleculin Biotech N/A -143.51% -24.53%

Does the media prefer CLNN or MBRX?

In the previous week, Clene had 1 more articles in the media than Moleculin Biotech. MarketBeat recorded 3 mentions for Clene and 2 mentions for Moleculin Biotech. Moleculin Biotech's average media sentiment score of 0.00 beat Clene's score of -0.24 indicating that Moleculin Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Clene 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Moleculin Biotech 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, MBRX or GRCE?

Grace Therapeutics is trading at a lower price-to-earnings ratio than Moleculin Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Moleculin Biotech N/A N/A -$33.56M -$7.13 N/A Grace Therapeutics N/A N/A -$7.79M -$1.18 N/A

Is MBRX or GRCE more profitable?

Grace Therapeutics' return on equity of -36.11% beat Moleculin Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Moleculin Biotech N/A -143.51% -24.53% Grace Therapeutics N/A -36.11% -34.39%

Does the media favor MBRX or GRCE?

In the previous week, Moleculin Biotech and Moleculin Biotech both had 2 articles in the media. Grace Therapeutics' average media sentiment score of 1.03 beat Moleculin Biotech's score of 0.00 indicating that Grace Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moleculin Biotech 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Grace Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend MBRX or RYM?

Moleculin Biotech presently has a consensus target price of $3.00, suggesting a potential upside of 468.29%. Given Moleculin Biotech's stronger consensus rating and higher possible upside, equities analysts clearly believe Moleculin Biotech is more favorable than RYTHM. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Moleculin Biotech 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 RYTHM 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is MBRX or RYM more profitable?

Moleculin Biotech has a net margin of 0.00% compared to RYTHM's net margin of -6.20%. RYTHM's return on equity of -12.57% beat Moleculin Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Moleculin Biotech N/A -143.51% -24.53% RYTHM -6.20% -12.57% -2.60%

Does the media prefer MBRX or RYM?

In the previous week, Moleculin Biotech and Moleculin Biotech both had 2 articles in the media. Moleculin Biotech's average media sentiment score of 0.00 equaled RYTHM'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moleculin Biotech 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral RYTHM 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to MBRX or SCYX?

In the previous week, SCYNEXIS had 1 more articles in the media than Moleculin Biotech. MarketBeat recorded 3 mentions for SCYNEXIS and 2 mentions for Moleculin Biotech. SCYNEXIS's average media sentiment score of 0.25 beat Moleculin Biotech's score of 0.00 indicating that SCYNEXIS is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moleculin Biotech 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SCYNEXIS 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Moleculin Biotech (MBRX) Competitors

$0.53 -0.04 (-6.57%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$0.50 -0.02 (-4.53%)

As of 09/23/2026 07:58 PM Eastern

Compare

MBRX vs. INCR, CLNN, GRCE, RYM, and SCYX

Should you buy Moleculin Biotech stock or one of its competitors? Moleculin Biotech's main competitors and comparable companies include InterCure (INCR), Clene (CLNN), Grace Therapeutics (GRCE), RYTHM (RYM), and SCYNEXIS (SCYX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Moleculin Biotech compare to InterCure?

InterCure (NASDAQ:INCR) and Moleculin Biotech (NASDAQ:MBRX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, media sentiment, analyst recommendations, profitability, risk, dividends and earnings.

InterCure has a beta of 1.42, meaning that its stock price is 42% more volatile than the broader market. Comparatively, Moleculin Biotech has a beta of 1.92, meaning that its stock price is 92% more volatile than the broader market.

In the previous week, Moleculin Biotech had 2 more articles in the media than InterCure. MarketBeat recorded 2 mentions for Moleculin Biotech and 0 mentions for InterCure. InterCure's average media sentiment score of 0.00 equaled Moleculin Biotech'saverage media sentiment score.

Company	Overall Sentiment
InterCure	Neutral
Moleculin Biotech	Neutral

8.3% of InterCure shares are owned by institutional investors. Comparatively, 15.5% of Moleculin Biotech shares are owned by institutional investors. 0.2% of InterCure shares are owned by company insiders. Comparatively, 18.0% of Moleculin Biotech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

InterCure's return on equity of 0.00% beat Moleculin Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InterCure	N/A	N/A	N/A
Moleculin Biotech	N/A	-143.51%	-24.53%

Moleculin Biotech has a consensus price target of $3.00, indicating a potential upside of 468.29%. Given Moleculin Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Moleculin Biotech is more favorable than InterCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InterCure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Moleculin Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

InterCure has higher revenue and earnings than Moleculin Biotech. Moleculin Biotech is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InterCure	$78.47M	0.76	-$10.37M	$0.15	36.47
Moleculin Biotech	N/A	N/A	-$33.56M	-$7.13	N/A

Summary

Moleculin Biotech beats InterCure on 7 of the 13 factors compared between the two stocks.

How does Moleculin Biotech compare to Clene?

Clene (NASDAQ:CLNN) and Moleculin Biotech (NASDAQ:MBRX) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and earnings.

23.3% of Clene shares are held by institutional investors. Comparatively, 15.5% of Moleculin Biotech shares are held by institutional investors. 28.3% of Clene shares are held by insiders. Comparatively, 18.0% of Moleculin Biotech shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Clene has higher revenue and earnings than Moleculin Biotech. Clene is trading at a lower price-to-earnings ratio than Moleculin Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Clene	$200K	278.64	-$26.17M	-$3.50	N/A
Moleculin Biotech	N/A	N/A	-$33.56M	-$7.13	N/A

In the previous week, Clene had 1 more articles in the media than Moleculin Biotech. MarketBeat recorded 3 mentions for Clene and 2 mentions for Moleculin Biotech. Moleculin Biotech's average media sentiment score of 0.00 beat Clene's score of -0.24 indicating that Moleculin Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Clene	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Moleculin Biotech	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Moleculin Biotech has a net margin of 0.00% compared to Clene's net margin of -20,063.96%. Clene's return on equity of 0.00% beat Moleculin Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Clene	-20,063.96%	N/A	-137.04%
Moleculin Biotech	N/A	-143.51%	-24.53%

Clene presently has a consensus price target of $34.00, suggesting a potential upside of 692.54%. Moleculin Biotech has a consensus price target of $3.00, suggesting a potential upside of 468.29%. Given Clene's stronger consensus rating and higher probable upside, equities research analysts clearly believe Clene is more favorable than Moleculin Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Clene	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Moleculin Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Clene has a beta of 0.95, meaning that its stock price is 5% less volatile than the broader market. Comparatively, Moleculin Biotech has a beta of 1.92, meaning that its stock price is 92% more volatile than the broader market.

Summary

Clene beats Moleculin Biotech on 10 of the 15 factors compared between the two stocks.

How does Moleculin Biotech compare to Grace Therapeutics?

Moleculin Biotech (NASDAQ:MBRX) and Grace Therapeutics (NASDAQ:GRCE) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, media sentiment, analyst recommendations and profitability.

Moleculin Biotech currently has a consensus price target of $3.00, suggesting a potential upside of 468.29%. Grace Therapeutics has a consensus price target of $6.00, suggesting a potential upside of 183.02%. Given Moleculin Biotech's stronger consensus rating and higher probable upside, equities research analysts plainly believe Moleculin Biotech is more favorable than Grace Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moleculin Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Grace Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Grace Therapeutics' return on equity of -36.11% beat Moleculin Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moleculin Biotech	N/A	-143.51%	-24.53%
Grace Therapeutics	N/A	-36.11%	-34.39%

Moleculin Biotech has a beta of 1.92, indicating that its share price is 92% more volatile than the broader market. Comparatively, Grace Therapeutics has a beta of 0.44, indicating that its share price is 56% less volatile than the broader market.

In the previous week, Moleculin Biotech and Moleculin Biotech both had 2 articles in the media. Grace Therapeutics' average media sentiment score of 1.03 beat Moleculin Biotech's score of 0.00 indicating that Grace Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moleculin Biotech	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Grace Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

15.5% of Moleculin Biotech shares are held by institutional investors. Comparatively, 6.1% of Grace Therapeutics shares are held by institutional investors. 18.0% of Moleculin Biotech shares are held by insiders. Comparatively, 10.8% of Grace Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Grace Therapeutics is trading at a lower price-to-earnings ratio than Moleculin Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moleculin Biotech	N/A	N/A	-$33.56M	-$7.13	N/A
Grace Therapeutics	N/A	N/A	-$7.79M	-$1.18	N/A

Summary

Moleculin Biotech beats Grace Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Moleculin Biotech compare to RYTHM?

Moleculin Biotech (NASDAQ:MBRX) and RYTHM (NASDAQ:RYM) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings.

15.5% of Moleculin Biotech shares are owned by institutional investors. Comparatively, 6.0% of RYTHM shares are owned by institutional investors. 18.0% of Moleculin Biotech shares are owned by insiders. Comparatively, 3.5% of RYTHM shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Moleculin Biotech and Moleculin Biotech both had 2 articles in the media. Moleculin Biotech's average media sentiment score of 0.00 equaled RYTHM'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moleculin Biotech	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
RYTHM	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Moleculin Biotech presently has a consensus target price of $3.00, suggesting a potential upside of 468.29%. Given Moleculin Biotech's stronger consensus rating and higher possible upside, equities analysts clearly believe Moleculin Biotech is more favorable than RYTHM.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moleculin Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
RYTHM	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Moleculin Biotech has a net margin of 0.00% compared to RYTHM's net margin of -6.20%. RYTHM's return on equity of -12.57% beat Moleculin Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moleculin Biotech	N/A	-143.51%	-24.53%
RYTHM	-6.20%	-12.57%	-2.60%

Moleculin Biotech has a beta of 1.92, indicating that its share price is 92% more volatile than the broader market. Comparatively, RYTHM has a beta of 9.44, indicating that its share price is 844% more volatile than the broader market.

RYTHM has higher revenue and earnings than Moleculin Biotech. RYTHM is trading at a lower price-to-earnings ratio than Moleculin Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moleculin Biotech	N/A	N/A	-$33.56M	-$7.13	N/A
RYTHM	$17.28M	2.90	-$33.26M	-$10.53	N/A

Summary

Moleculin Biotech beats RYTHM on 8 of the 13 factors compared between the two stocks.

How does Moleculin Biotech compare to SCYNEXIS?

Moleculin Biotech (NASDAQ:MBRX) and SCYNEXIS (NASDAQ:SCYX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, dividends, analyst recommendations, institutional ownership, valuation and profitability.

In the previous week, SCYNEXIS had 1 more articles in the media than Moleculin Biotech. MarketBeat recorded 3 mentions for SCYNEXIS and 2 mentions for Moleculin Biotech. SCYNEXIS's average media sentiment score of 0.25 beat Moleculin Biotech's score of 0.00 indicating that SCYNEXIS is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moleculin Biotech	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
SCYNEXIS	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

SCYNEXIS has higher revenue and earnings than Moleculin Biotech. SCYNEXIS is trading at a lower price-to-earnings ratio than Moleculin Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moleculin Biotech	N/A	N/A	-$33.56M	-$7.13	N/A
SCYNEXIS	$20.60M	2.24	-$8.61M	-$2.09	N/A

Moleculin Biotech has a beta of 1.92, suggesting that its share price is 92% more volatile than the broader market. Comparatively, SCYNEXIS has a beta of 1.11, suggesting that its share price is 11% more volatile than the broader market.

15.5% of Moleculin Biotech shares are held by institutional investors. Comparatively, 54.4% of SCYNEXIS shares are held by institutional investors. 18.0% of Moleculin Biotech shares are held by company insiders. Comparatively, 4.1% of SCYNEXIS shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Moleculin Biotech has a net margin of 0.00% compared to SCYNEXIS's net margin of -41.79%. SCYNEXIS's return on equity of -44.15% beat Moleculin Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moleculin Biotech	N/A	-143.51%	-24.53%
SCYNEXIS	-41.79%	-44.15%	-32.61%

Moleculin Biotech presently has a consensus price target of $3.00, indicating a potential upside of 468.29%. SCYNEXIS has a consensus price target of $33.00, indicating a potential upside of 611.21%. Given SCYNEXIS's higher possible upside, analysts clearly believe SCYNEXIS is more favorable than Moleculin Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moleculin Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
SCYNEXIS	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

SCYNEXIS beats Moleculin Biotech on 8 of the 13 factors compared between the two stocks.

Get Moleculin Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MBRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MBRX vs. The Competition

Export

Metric	Moleculin Biotech	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$11.01M	$12.59B	$7.32B	$13.29B
Dividend Yield	N/A	2.62%	2.52%	12.57%
P/E Ratio	-0.07	792.28	274.01	25.69
Price / Sales	N/A	857.20	656.83	89.15
Price / Cash	N/A	88.64	77.80	52.76
Price / Book	0.11	10.62	10.44	6.32
Net Income	-$33.56M	$2.81B	$3.49B	$359.73M
7 Day Performance	-32.32%	-0.07%	-0.66%	0.17%
1 Month Performance	-13.36%	-1.30%	-3.16%	-3.27%
1 Year Performance	-95.04%	2.93%	15.15%	5.58%

Moleculin Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MBRX Moleculin Biotech	3.0706 of 5 stars	$0.53 -6.6%	$3.00 +468.3%	-95.1%	$11.01M	N/A	N/A	17	News Coverage Gap Up
INCR InterCure	1.1899 of 5 stars	$5.31 +3.5%	N/A	-24.6%	$56.10M	$78.47M	35.40	350
CLNN Clene	1.913 of 5 stars	$3.86 -4.0%	$34.00 +780.8%	-29.9%	$51.65M	$200K	N/A	100	High Trading Volume
GRCE Grace Therapeutics	2.027 of 5 stars	$2.14 -4.0%	$6.00 +180.4%	-31.8%	$46.91M	N/A	N/A	N/A	Positive News
RYM RYTHM	0.4383 of 5 stars	$20.88 -2.5%	N/A	-39.2%	$46.69M	$17.28M	N/A	140	Positive News Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MBRX) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Moleculin Biotech (MBRX) Competitors

MBRX vs. INCR, CLNN, GRCE, RYM, and SCYX

How does Moleculin Biotech compare to InterCure?

Summary

How does Moleculin Biotech compare to Clene?

Summary

How does Moleculin Biotech compare to Grace Therapeutics?

Summary

How does Moleculin Biotech compare to RYTHM?

Summary

How does Moleculin Biotech compare to SCYNEXIS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MBRX vs. The Competition

Moleculin Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Moleculin Biotech (MBRX) Competitors

MBRX vs. INCR, CLNN, GRCE, RYM, and SCYX

How does Moleculin Biotech compare to InterCure?

Which has more volatility & risk, INCR or MBRX?

Does the media refer more to INCR or MBRX?

Do insiders and institutionals believe in INCR or MBRX?

Is INCR or MBRX more profitable?

Do analysts prefer INCR or MBRX?

Which has better earnings and valuation, INCR or MBRX?

Summary

How does Moleculin Biotech compare to Clene?

Do insiders & institutionals hold more shares of CLNN or MBRX?

Which has stronger earnings & valuation, CLNN or MBRX?

Does the media prefer CLNN or MBRX?

Is CLNN or MBRX more profitable?

Do analysts prefer CLNN or MBRX?

Which has more risk & volatility, CLNN or MBRX?

Summary

How does Moleculin Biotech compare to Grace Therapeutics?

Do analysts recommend MBRX or GRCE?

Is MBRX or GRCE more profitable?

Which has more volatility & risk, MBRX or GRCE?

Does the media favor MBRX or GRCE?

Do insiders and institutionals hold more shares of MBRX or GRCE?

Which has stronger earnings and valuation, MBRX or GRCE?

Summary

How does Moleculin Biotech compare to RYTHM?

Do institutionals and insiders hold more shares of MBRX or RYM?

Does the media prefer MBRX or RYM?

Do analysts recommend MBRX or RYM?

Is MBRX or RYM more profitable?

Which has more volatility and risk, MBRX or RYM?

Which has higher valuation and earnings, MBRX or RYM?

Summary

How does Moleculin Biotech compare to SCYNEXIS?

Does the media refer more to MBRX or SCYX?

Which has preferable valuation and earnings, MBRX or SCYX?

Which has more risk and volatility, MBRX or SCYX?

Do institutionals & insiders believe in MBRX or SCYX?

Is MBRX or SCYX more profitable?

Do analysts recommend MBRX or SCYX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MBRX vs. The Competition

Moleculin Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools